Hodges Capital Management Inc. Has $12.35 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Hodges Capital Management Inc. lessened its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 41.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 193,565 shares of the biopharmaceutical company’s stock after selling 139,389 shares during the period. Halozyme Therapeutics accounts for 1.2% of Hodges Capital Management Inc.’s portfolio, making the stock its 20th largest position. Hodges Capital Management Inc. owned 0.16% of Halozyme Therapeutics worth $12,351,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in HALO. Isthmus Partners LLC grew its holdings in shares of Halozyme Therapeutics by 2.5% in the 1st quarter. Isthmus Partners LLC now owns 6,875 shares of the biopharmaceutical company’s stock valued at $439,000 after buying an additional 169 shares during the period. OneDigital Investment Advisors LLC grew its holdings in shares of Halozyme Therapeutics by 1.7% in the 1st quarter. OneDigital Investment Advisors LLC now owns 10,176 shares of the biopharmaceutical company’s stock valued at $649,000 after buying an additional 175 shares during the period. Park Place Capital Corp grew its holdings in shares of Halozyme Therapeutics by 20.1% in the 1st quarter. Park Place Capital Corp now owns 1,086 shares of the biopharmaceutical company’s stock valued at $69,000 after buying an additional 182 shares during the period. Xponance Inc. grew its holdings in shares of Halozyme Therapeutics by 1.1% in the 1st quarter. Xponance Inc. now owns 18,652 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 198 shares during the period. Finally, Bessemer Group Inc. grew its holdings in shares of Halozyme Therapeutics by 62.9% in the 1st quarter. Bessemer Group Inc. now owns 536 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 207 shares during the period. Institutional investors and hedge funds own 97.79% of the company’s stock.

Insider Buying and Selling

In other news, CFO Nicole Labrosse sold 20,000 shares of the stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the transaction, the chief financial officer directly owned 24,306 shares in the company, valued at $1,840,207.26. This represents a 45.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $63.51, for a total transaction of $1,270,200.00. Following the transaction, the chief executive officer owned 733,719 shares of the company’s stock, valued at approximately $46,598,493.69. This represents a 2.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 124,000 shares of company stock valued at $7,830,320. Company insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of NASDAQ HALO opened at $77.53 on Friday. The firm has a market cap of $9.07 billion, a PE ratio of 17.74, a PEG ratio of 0.42 and a beta of 1.19. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54. Halozyme Therapeutics, Inc. has a 1-year low of $42.01 and a 1-year high of $77.58. The company has a fifty day moving average price of $64.65 and a 200 day moving average price of $60.32.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million during the quarter, compared to analyst estimates of $282.66 million. Halozyme Therapeutics had a net margin of 47.28% and a return on equity of 150.85%. The company’s revenue for the quarter was up 40.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Research analysts predict that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on HALO shares. Zacks Research raised shares of Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 2nd. Wall Street Zen lowered shares of Halozyme Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, September 5th. JMP Securities boosted their price target on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a “market outperform” rating in a report on Wednesday, August 6th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, August 6th. Finally, The Goldman Sachs Group started coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. They issued a “neutral” rating and a $55.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Halozyme Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $67.11.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.